MediWound : Presentation - January 2023

Non-Surgical Biological Solutions for Tissue Repair & Regeneration

January 2023 I Nasdaq: MDWD

Cautionary Note Regarding Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial potential of our products and product candidates, the anticipated development progress of our products and product candidates, and our expected cash runaway. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Important factors that could cause such differences include, but are not limited to the uncertain, lengthy and expensive nature of the product development process; market acceptance of our products and product candidates; the timing and conduct of our studies of our product candidates; our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; our expectations regarding future growth, including our ability to develop new products; risks related to our contracts with BARDA; our ability to maintain adequate protection of our intellectual property; competition risks; and the need for additional financing. These and other significant factors are discussed in greater detail in MediWound's annual report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission ("SEC") on March 17, 2022, and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound's current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law

Certain studies and data presented herein have been conducted for us by other entities as indicated where relevant. Intellectual property, including patents, copyrights or trade secret displayed in this presentation, whether registered or unregistered, are the intellectual property rights of MediWound. MediWound's name and logo and other MediWound product names, slogans and logos referenced in this presentation are trademarks of MediWound Ltd. and/or its subsidiaries, registered in the U.S.A., EU member states and Israel.

NexoBrid development has been supported in part with federal funding from U.S. Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), under ongoing USG Contract numbers HHSO100201500035C and HHSO100201800023C. Contract number HHSO100201500035C provides funding and technical support for the pivotal U.S. Phase 3 clinical study (DETECT) and the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access treatment protocol (NEXT) in the U.S. Additional projects for evaluation of NexoBrid funded under the BARDA contract include randomized, controlled pivotal clinical trial for use in pediatric population, establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market adoption in the United States.

We maintain our books and records in U.S. dollars and report under IFRS.

2

Company Highlights

Validated enzymatic technology platform

FDA/EMA/PMDA approvals

14 successful clinical trials 120+peer reviewed publications

Global strategic collaborations

BARDA, Vericel, DoD (US),

Kaken (JP), BSV (IN)

Diversified		cGMP certified sterile
portfolio		manufacturing facility

NexoBrid® - 2022 revenues: $26-27M		Provides capacity to scale
EscharEx® - $2B* opportunity		revenue growth

Solid balance sheet

& strong investor base

$42M cash

Runway through 2025

*TAM - targeted addressable market; Source: Oliver Wyman market research

3

Leadership Team

Nachum (Homi) Shamir	Ofer Gonen	Prof. Lior Rosenberg	Dr. Ety Klinger	Tzvi Palash	Boaz Gur-Lavie	Dr. Robert J. Snyder
Chairman of the Board	Chief Executive Officer	Founder, Medical Director	Chief R&D Officer	Chief Operating Officer	Chief Financial Officer	Chief Medical Officer

4

Proprietary Enzymatic Technology Platform

Clinically and commercially validated	Selective enzymes target only
protein-based therapies	non-viable tissue

Pineapple stem

Protein

harvest

extraction

Healthy skin

Damaged skin

Viable tissues preserved; healing begins

Purification, enrichment,	Complex mixture of
stabilization	proteolytic enzymes

Images modified from Labster theory and bioinfo

5